Atherosclerosis, Supplements

Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase
pp. 1-3(3)
Authors: Boger R.H.; Vallance P.; Cooke J.P.

Old and new cardiovascular risk factors: from unresolved issues to new opportunities
pp. 5-17(13)
Authors: Maas R.; Boger R.H.

Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events - Does statin treatment influence plasma ADMA levels?
pp. 19-22(4)
Authors: Valkonen V.-P.; Laakso J.; Paiva H.; Lehtimaki T.; Lakka T.A.; Isomustajarvi M.; Ruokonen I.; Salonen J.T.; Laaksonen R.

ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease
pp. 23-28(6)
Authors: Boger R.H.; Zoccali C.

Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study
pp. 29-32(4)
Authors: Mugge A.; Hanefeld C.; Boger R.H.; CARDIAC study investigators

The DDAH/ADMA/NOS pathway
pp. 33-40(8)
Authors: Tran C.T.L.; Leiper J.M.; Vallance P.

ADMA and oxidative stress
pp. 41-51(11)
Authors: Sydow K.; Munzel T.

NO and angiogenesis
pp. 53-60(8)
Author: Cooke J.P.

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA
pp. 61-65(5)
Authors: Lentz S.R.; Rodionov R.N.; Dayal S.